Witten James C, Houghtaling Penny L, Shrestha Nabin K, Gordon Steven M, Jaber Wael, Blackstone Eugene H, Pettersson Gösta B
Department of Thoracic and Cardiovascular Surgery, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio.
Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
J Thorac Cardiovasc Surg. 2023 Apr;165(4):1303-1315.e9. doi: 10.1016/j.jtcvs.2021.04.086. Epub 2021 May 12.
Intrinsic risk of infection of cryopreserved allograft aortic root replacements remains poorly understood despite their long history of use. The objective of this study was to determine this intrinsic risk of allograft infection and its risk factors when allografts are implanted for both nonendocarditis indications and infective endocarditis.
From January 1987 to January 2017, 2042 patients received 2110 allograft aortic valves at a quaternary medical center, 1124 (53%) for nonendocarditis indications and 986 (47%) for endocarditis indications (670 [68%] prosthetic valve endocarditis). Staphylococcus aureus caused 193 of 949 cases of endocarditis (20%), 71 (7.3%) in persons who injected drugs. Periodic surveillance and cross-sectional follow-up achieved 85% of possible follow-up time. The primary end point was allograft infection in patients with nonendocarditis and endocarditis indications. Risk factors were identified by hazard function decomposition and machine learning.
During follow-up, 30 allografts (26 explanted) became infected in patients in the nonendocarditis group and 49 (41 explanted) in patients with endocarditis. At 20 years, the probability of allograft infection was 5.6% in patients in the nonendocarditis group and 14% in patients with endocarditis. Risk factors for allograft infection in patients in the nonendocarditis group were younger patient age and older donor age. Risk factors for allograft infection in patients with endocarditis were earlier implant year, injection drug use, and younger age. In patients with endocarditis, 18% of allograft infections were caused by the original organism.
The low infection rates, both in patients without and with endocarditis, support continued use of allografts in the modern era, in particular for the treatment of invasive endocarditis of the aortic root.
尽管冷冻保存的同种异体主动脉根部置换术应用历史悠久,但其内在感染风险仍知之甚少。本研究的目的是确定同种异体移植物植入用于非心内膜炎适应证和感染性心内膜炎时的这种内在感染风险及其危险因素。
从1987年1月至2017年1月,一家四级医疗中心的2042例患者接受了2110个同种异体主动脉瓣膜,其中1124例(53%)用于非心内膜炎适应证,986例(47%)用于心内膜炎适应证(670例[68%]为人工瓣膜心内膜炎)。金黄色葡萄球菌导致949例心内膜炎中的193例(20%),其中71例(7.3%)发生在注射毒品者中。定期监测和横断面随访实现了85%的可能随访时间。主要终点是非心内膜炎和心内膜炎适应证患者的同种异体移植物感染。通过风险函数分解和机器学习确定危险因素。
随访期间,非心内膜炎组患者中有30个同种异体移植物(26个被取出)发生感染,心内膜炎患者中有49个(41个被取出)发生感染。在20年时,非心内膜炎组患者同种异体移植物感染的概率为5.6%,心内膜炎患者为14%。非心内膜炎组患者同种异体移植物感染的危险因素是患者年龄较小和供体年龄较大。心内膜炎患者同种异体移植物感染的危险因素是植入年份较早、注射毒品和年龄较小。在心内膜炎患者中,18%的同种异体移植物感染由原始病原体引起。
无论有无心内膜炎,感染率都很低,这支持在现代继续使用同种异体移植物,特别是用于治疗主动脉根部的侵袭性心内膜炎。